- Conditions
- Myelodysplastic Syndromes
- Interventions
- Elritercept, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 25
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 5,300
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ethmoid Sinusitis
- Interventions
- Sinopsys Lacrimal Stent
- Device
- Lead sponsor
- Sinopsys Surgical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Stanford, California • Greeley, Colorado • Louisville, Kentucky
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
- Interventions
- daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 256
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 198 more
- Conditions
- Subjective Tinnitus
- Interventions
- Neramexane mesylate
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 821 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Burbank, California • Fresno, California + 27 more
- Conditions
- Severe Sepsis
- Interventions
- Drotrecogin alfa (activated)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 491
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more
- Conditions
- Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
- Interventions
- Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
- Conditions
- Male Osteoporosis
- Interventions
- Ibandronate, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 30 Years and older · Male only
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 36 more
- Conditions
- Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency
- Interventions
- Myozyme® (alglucosidase alfa)
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Durham, North Carolina • Salt Lake City, Utah + 1 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 638
- States / cities
- Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more
- Conditions
- Enterovirus Infection
- Interventions
- Placebo, Pleconaril
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 0 Days to 15 Days
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Sarcoma
- Interventions
- Trabectedin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 31
- States / cities
- Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
- Conditions
- Crohn's Disease
- Interventions
- Infliximab, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
- Interventions
- LP-184, Olaparib, Nivolumab & Ipilimumab
- Drug
- Lead sponsor
- Lantern Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Melflufen, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Oncopeptides AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Inhaled Nitric Oxide, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 5 Days to 14 Days
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
- Procedure · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- P38 Inhibitor (4), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Scottsdale, Arizona • Tucson, Arizona + 18 more
- Conditions
- Acute Pain
- Interventions
- IV Acetaminophen, IV Control
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Orange, California • San Diego, California + 19 more
- Conditions
- Congestive Heart Failure
- Interventions
- Cardiac Compass with OptiVol Fluid Status Monitoring, Standard of Care alone (clinical assessment)
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Berkeley, California + 30 more
- Conditions
- Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
- Interventions
- Vimizim® (elosulfase alfa)
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
- Conditions
- Melanoma
- Interventions
- A-dmDT390-bisFv(UCHT1) (Resimmune®), Ionizing Radiation
- Drug · Radiation
- Lead sponsor
- Virogen Biotechnology Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Acne
- Interventions
- Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 9
- States / cities
- Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 341
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more